System for inducing sonoporation of a drug into cancer cells and method thereof
A drug and sound hole technology, applied in the field of systems, can solve problems such as difficult to ensure ultrasound
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment approach
[0067] Preferred embodiments of the system of the present invention include:
[0068] - a generator configured to provide electrical energy at an ultrasonic frequency;
[0069] - an ultrasound probe electrically connected to the generator and configured to:
[0070] Converting electrical energy into low-intensity non-focused pulsed ultrasound defined by operating parameters including frequency, duty cycle and operating time of the ultrasound;
[0071] - an input device enabling the operator to enter configuration data including tumor type, drug type, anthropometric values and tumor grade of the patient to which the cancer cell belongs; and
[0072] - a processor configured to:
[0073] Determining values of said operating parameters based on the input configuration data, wherein the value of frequency is determined based on tumor type and anthropometric values, the value of duty cycle is determined based on at least drug type and tumor type; and
[0074] • Controlling t...
Embodiment 1
[0123] In the table below, the percentage of cell death is reported for MCF-7 cells administered with three different concentrations of paclitaxel under three conditions:
[0124] -None-US: the first dose with the first dose of paclitaxel without administration of ultrasound (None-US), followed by the second dose with the second dose of paclitaxel;
[0125] - US-DC = 12%: first dose of paclitaxel with the first dose, pLINFU (with duty cycle = 12%) administered simultaneously for 20 seconds, followed by a second dose of paclitaxel with the second dose, Simultaneously reapply pLINFU for 20 seconds;
[0126] - US-DC = 9%: first dose of paclitaxel with the first dose, pLINFU (with duty cycle = 9%) administered simultaneously for 20 seconds, followed by a second dose of paclitaxel for the second dose, At the same time pLINFU was administered for an additional 20 seconds.
[0127]
[0128] The results of the above table are represented graphically in the Figure 1a middle.
Embodiment 2
[0130] In the table below, the percentage of cell death following administration of three different concentrations of paclitaxel albumin to MCF-7 cells under three conditions is reported:
[0131] -None-US: the first dose with the first dose of paclitaxel albumin, but without administration of ultrasound (None-US), followed by the second dose with the second dose of paclitaxel albumin;
[0132] - US-DC = 12%: 1st dose of paclitaxel albumin for the first dose, concurrently administering pLINFU (with duty cycle = 12%) for 20 seconds, followed by a second dose of paclitaxel albumin Administration for the first time, and pLINFU was administered for 20 seconds at the same time;
[0133] - US-DC=9%: 1st dose of paclitaxel albumin with first dose, pLINFU (with duty cycle = 9%) administered simultaneously for 20 seconds, followed by second dose of paclitaxel albumin The second dose was administered concurrently with pLINFU for an additional 20 seconds.
[0134]
[0135] The resul...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com